The involvement of the NLRP3 inflammasome in several inflammatory conditions has made it an attractive potential pharmacological target and, thus, the therapeutic utility of blocking the IL-1 pathway by using, for example, anakinra, the recombinant inhibitor of human IL-1R, which was approved for the treatment of certain autoimmune disorders, has been tested in various hematological conditions with variable results [76,79]. Here, IL1A is linked to autoimmune disease.